AstraZeneca Korea Disputes Results from Latest Asthma Study

Published: 2005-04-12 06:58:00

Updated: 2005-04-12 06:58:00

AstraZeneca Korea said the results from the CONCEPT (CONtrol CEntered Patient Treatment) study, which claimed the stable-dose Seretide (salmeterol/fluticasone propionate combination) is more effective over the adjustable maintenance dose Symbicort (formoterol/budesonide), are in conflict with evidence from eight previous clinical trials involvingmore than 10,000 patients.

The CONCEPT study, ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.